Coral Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -1330.61%
- Ebitda 74.79%
- Net Worth -24.89%
- Total Assets -98.37%
About Coral Biosciences
Coral Biosciences Private Limited (CBPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 February 2018 (Six years and 11 months 18 days old ). Its registered office is in Delhi, Delhi, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashutosh Goyal and Prateek Goyal serve as directors at the Company.
Company Details
-
Location
Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U33125DL2018PTC329701
-
Company No.
329701
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Feb 2018
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Coral Biosciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashutosh Goyal
|
Director | 20-Feb-2018 | Current |
|
Prateek Goyal
|
Director | 20-Feb-2018 | Current |
Financial Performance of Coral Biosciences.
Coral Biosciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1330.61% decrease in profit. The company's net worth observed a substantial decline by a decrease of 24.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Coral Biosciences?
In 2023, Coral Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Coral Biocals LlpAshutosh Goyal and Prateek Goyal are mutual person
-
Orange Biologicals Private Limited
Ashutosh Goyal and Prateek Goyal are mutual person
-
Kiana Overseas Private Limited
Ashutosh Goyal is a mutual person
-
Asv Biotech Llp
Prateek Goyal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Coral Biosciences?
Unlock and access historical data on people associated with Coral Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Coral Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Coral Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.